文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

[18F]MFBG PET显像:神经嵴肿瘤患者的生物分布、药代动力学及与[123I]MIBG的比较

[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-11-26

这项前瞻性试验纳入6例神经嵴肿瘤患者(4例嗜铬细胞瘤、1例副神经节瘤、1例神经母细胞瘤),评估[18F]MFBG的安全性、生物分布、肿瘤病灶药代动力学及病灶靶向性,并与[123I]MIBG进行头对头比较。[18F]MFBG安全且耐受良好,生物分布与[123I]MIBG总体相似;[123I]MIBG检出的所有病灶[18F]MFBG均可见,[123I]MIBG的平均检出率显著低于[18F]MFBG(1小时61.0%±26.7% vs 99.8%±0.5%,p=0.043)。

要点

  • [18F]MFBG安全且耐受良好,生物分布与[123I]MIBG总体相似。
  • 嗜铬细胞瘤亚组中位VT为37.4 mL/cm3(范围18.0-144.8),VT与SUVmean在3个时间点均高度相关(R2:0.92-0.94)。
  • [123I]MIBG检出的所有病灶[18F]MFBG均可见,平均检出率[123I]MIBG显著低于[18F]MFBG。

核心结论

  • [18F]MFBG是一种有前景的hNET显像剂,与[123I]MIBG闪烁显像相比具有有利的显像特征并改善了病灶靶向性。

研究设计与样本

  • 前瞻性试验纳入6例神经嵴肿瘤患者(4例嗜铬细胞瘤、1例副神经节瘤、1例神经母细胞瘤),均在近期(间隔-37至75天)接受过常规临床[123I]MIBG闪烁显像。
  • 5例成人患者注射4 MBq/kg [18F]MFBG后行30分钟动态PET,并于注射后60、120、180分钟行3次全身PET/CT扫描。
  • 1例未成年受试者给予2 MBq/kg [18F]MFBG后于60分钟行单次全身PET/CT。
  • 测量正常器官摄取(SUVmean)和病灶摄取(SUVmax;肿瘤-本底比TBR),采用Logan图形分析估计每例患者最多6个病灶的局部分布容积VT。
  • 进行逐病灶分析,比较[18F]MFBG与[123I]MIBG的检出率(DR),即检出病灶的比例。

主要发现

  • [18F]MFBG安全且耐受良好,生物分布与[123I]MIBG总体相似,唾液腺、肝脏、左心室壁和肾上腺摄取明显,主要经尿液排泄。
  • 嗜铬细胞瘤亚组中位VT为37.4 mL/cm3(范围18.0-144.8),VT与SUVmean在全部3个时间点均高度相关(R2:0.92-0.94)。
  • 注射后1小时平均病灶SUVmax为19.3±10.7,TBR为23.6±8.4。
  • [123I]MIBG检出的所有病灶[18F]MFBG也均观察到。
  • [123I]MIBG平均检出率显著低于[18F]MFBG(1小时61.0%±26.7% vs 99.8%±0.5%,p=0.043)。

关键数值与推荐

  • 成人剂量为4 MBq/kg [18F]MFBG,未成年受试者剂量为2 MBq/kg [18F]MFBG。
  • 嗜铬细胞瘤亚组中位VT为37.4 mL/cm3(范围18.0-144.8)。
  • 注射后1小时平均病灶SUVmax为19.3±10.7,TBR为23.6±8.4。
  • 1小时平均检出率[123I]MIBG为61.0%±26.7%,[18F]MFBG为99.8%±0.5%(p=0.043)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite its limitations, [123I]MIBG scintigraphy has been the standard for human norepinephrine transporter (hNET) imaging for several decades. Recently, [18F]MFBG has emerged as a promising PET alternative. This prospective trial aimed to evaluate safety, biodistribution, tumour lesion pharmacokinetics, and lesion targeting of [18F]MFBG and perform a head-to-head comparison with [123I]MIBG in neural crest tumour patients. METHODS: Six neural crest tumour patients (4 phaeochromocytoma, 1 paraganglioma, 1 neuroblastoma) with a recent routine clinical [123I]MIBG scintigraphy (interval: - 37-75 days) were included. Adult patients (n = 5) underwent a 30-min dynamic PET, followed by 3 whole-body PET/CT scans at 60, 120, and 180 min after injection of 4 MBq/kg [18F]MFBG. One minor participant underwent a single whole-body PET/CT at 60 min after administration of 2 MBq/kg [18F]MFBG. Normal organ uptake (SUVmean) and lesion uptake (SUVmax; tumour-to-background ratio (TBR)) were measured. Regional distribution volumes (VT) were estimated using a Logan graphical analysis in up to 6 lesions per patient. A lesion-by-lesion analysis was performed to compare detection ratios (DR), i.e. fraction of detected lesions, between [18F]MFBG and [123I]MIBG. RESULTS: [18F]MFBG was safe and well tolerated. Its biodistribution was overall similar to that of [123I]MIBG, with prominent uptake in the salivary glands, liver, left ventricle wall and adrenals, and mainly urinary excretion. In the phaeochromocytoma subgroup, the median VT was 37.4 mL/cm3 (range: 18.0-144.8) with an excellent correlation between VT and SUVmean at all 3 time points (R2: 0.92-0.94). Mean lesion SUVmax and TBR at 1 h after injection were 19.3 ± 10.7 and 23.6 ± 8.4, respectively. All lesions detected with [123I]MIBG were also observed with [18F]MFBG. The mean DR with [123I]MIBG was significantly lower than with [18F]MFBG (61.0% ± 26.7% vs. 99.8% ± 0.5% at 1 h; p = 0.043). CONCLUSION: [18F]MFBG is a promising hNET imaging agent with favourable imaging characteristics and improved lesion targeting compared with [123I]MIBG scintigraphy. TRIAL REGISTRATION: Clinicaltrials.gov : NCT04258592 (Registered: 06 February 2020), EudraCT: 2019-003872-37A.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pauwels E, Celen S, Baete K, et al. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients. Eur J Nucl Med Mol Imaging. 2022. PMID: 36435928. doi:10.1007/s00259-022-06046-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。